111 Capital Sells 7,601 Shares of Halozyme Therapeutics, Inc. $HALO

111 Capital reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 57.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,637 shares of the biopharmaceutical company’s stock after selling 7,601 shares during the quarter. 111 Capital’s holdings in Halozyme Therapeutics were worth $413,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Campbell Newman Asset Management Inc. grew its position in shares of Halozyme Therapeutics by 0.4% during the 3rd quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock worth $2,705,000 after buying an additional 153 shares during the period. Alps Advisors Inc. raised its holdings in shares of Halozyme Therapeutics by 3.0% during the third quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company’s stock worth $435,000 after acquiring an additional 170 shares during the period. EverSource Wealth Advisors LLC grew its holdings in shares of Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 174 shares in the last quarter. Richardson Financial Services Inc. lifted its position in shares of Halozyme Therapeutics by 87.6% in the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares in the last quarter. Finally, Brown Advisory Inc. raised its holdings in Halozyme Therapeutics by 0.6% during the second quarter. Brown Advisory Inc. now owns 35,057 shares of the biopharmaceutical company’s stock worth $1,824,000 after acquiring an additional 224 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00. Following the transaction, the chief executive officer owned 708,719 shares of the company’s stock, valued at approximately $53,947,690.28. The trade was a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares of the company’s stock, valued at $2,818,640.75. This trade represents a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 32,000 shares of company stock worth $2,449,300 over the last three months. 2.90% of the stock is owned by insiders.

Analyst Ratings Changes

HALO has been the topic of a number of research reports. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday, February 24th. Benchmark increased their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Finally, The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and a consensus target price of $78.56.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $69.40 on Wednesday. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. The firm has a fifty day simple moving average of $72.68 and a two-hundred day simple moving average of $70.76. Halozyme Therapeutics, Inc. has a 12 month low of $47.50 and a 12 month high of $82.22. The firm has a market capitalization of $8.19 billion, a PE ratio of 27.87, a price-to-earnings-growth ratio of 0.28 and a beta of 0.98.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The business had revenue of $451.77 million for the quarter, compared to analyst estimates of $446.13 million. During the same quarter in the prior year, the business earned $1.26 earnings per share. The firm’s quarterly revenue was up 51.6% compared to the same quarter last year. Analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.